315
Views
3
CrossRef citations to date
0
Altmetric
Review

Considerations on long-term immuno-intervention in the treatment of multiple sclerosis: an expert opinion

, , , &
Pages 2085-2095 | Received 20 May 2016, Accepted 01 Sep 2016, Published online: 15 Sep 2016

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Francois Grand’Maison, Michael Yeung, Sarah A. Morrow, Liesly Lee, Francois Emond, Brian J. Ward, Pierre Laneuville & Robyn Schecter. (2018) Sequencing of disease-modifying therapies for relapsing–remitting multiple sclerosis: a theoretical approach to optimizing treatment. Current Medical Research and Opinion 34:8, pages 1419-1430.
Read now

Articles from other publishers (2)

Ricardo Alonso, Edgar Carnero Contentti, Gaston Imhoff, Pablo A. Lopez, Adrian Rubstein & Santiago Tizio. (2019) Barriers against a successful MS treatment: The importance of effectiveness beyond efficacy. Multiple Sclerosis and Related Disorders 30, pages 129-135.
Crossref
Gavin Giovannoni, Heinz Wiendl, Benjamin Turner, Kimberly Umans, Oksana Mokliatchouk, Wanda Castro-Borrero, Steven J Greenberg, Peter McCroskery & Giorgio Giannattasio. (2017) Circulating lymphocyte levels and relationship with infection status in patients with relapsing–remitting multiple sclerosis treated with daclizumab beta. Multiple Sclerosis Journal 24:13, pages 1725-1736.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.